Randomized Phase II Trial of Short-Course Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local Therapy

Inclusion Criteria:

- History of biopsy documented prostate cancer (any Gleason score)

- Past treatment with prostatectomy with or without salvage prostate/pelvic radiation
or primary radiation (external beam or brachytherapy)

- If past prostatectomy, pathologic stage no greater than T1-3, N1, M0

- PSA recurrence with PSAdt < 18 months. There is no minimum PSA for prostatectomy
patients. For patients treated with primary radiation therapy PSA should be greater
than 2.0 ng/ml

- No evidence of recurrent disease on exam, bone scan, CT/MRI abdomen/pelvis or CXR

- Prior ADT allowed if < 6 months and testosterone recovered to within 50 units (ng/dl)
of normal range

- ECOG Performance status of 0-1

- Absolute neutrophil count of >1,500

- Platelet count > 100,000

- Hg > 8g/dl

- No history of bleeding or thromboses within the last 12 months that required medical
intervention

Exclusion Criteria:

- History of cancer within 5 years, other than prostate cancer and non-melanoma skin
cancer

- Medical condition requiring concomitant corticosteroids

- Active infection

- Prior chemotherapy allowed if was < 6 cycles and > 6 months prior to study entry

- Documented local recurrence or metastatic prostate cancer

- Inability to comply with study and/or follow-up procedures

- Life expectancy of less than 2 years

- Current, recent (within 4 weeks of the first infusion of this study), or planned
participation in an experimental drug study other than a Genentech-sponsored
bevacizumab cancer study